Dr. Loïc Djaileb explores the use of RECIP 1.0 criteria with SPECT/CT and the efficacy of this strategy in monitoring mCRPC.
Prostate Cancer
Advertisement
Latest News
Drs. Tagawa and Marulanda Corzo discuss the use of single time-point SPECT/CT dosimetry for 177Lu-PSMA targeted RLT.
Dr. Nadine Mallak talks about 18F-fluciclovine to detect disease in BCR of prostate cancer when the standard of care fails.
Phase 3 EMBARK trial results show promising survival benefits of combination therapy in patients with nmHSPC.
Dr. Miles highlights the dilemma of managing PC with BCR after prostatectomy but no visible disease on standard imaging.
The panel discusses the evolving treatment landscape for mCRPC, focusing on the role of RLTs and PARP inhibitors.
The panel discusses treatment intensification strategies for mCSPC, emphasizing the shift toward doublet and triplet therapy.
Prostate Cancer Knowledge Hubs
Curated clinical content on prostate cancer types, therapies, and technologies
Advertisement
Conference Coverage
Drs. Tagawa and Marulanda Corzo discuss the use of single time-point SPECT/CT dosimetry for 177Lu-PSMA targeted RLT.
Dr. Nadine Mallak talks about 18F-fluciclovine to detect disease in BCR of prostate cancer when the standard of care fails.
Dr. Miles highlights the dilemma of managing PC with BCR after prostatectomy but no visible disease on standard imaging.
Dr. Kimura shares insights on PSMA PET/CT metrics and their potential role in guiding treatment decisions for mCRPC.
Professor Bex discusses the phase II NEOAVAX trial that evaluated avelumab/axitinib as neoadjuvant therapy in localized RCC.
Samer Srour, MB, talks about the updated ALLO-316 and its use in targeting CD70 in patients with advanced ccRCC.
Advertisement
Advertisement
Trending
Drs. Tagawa and Marulanda Corzo discuss the use of single time-point SPECT/CT dosimetry for 177Lu-PSMA targeted RLT.
Dr. Nadine Mallak talks about 18F-fluciclovine to detect disease in BCR of prostate cancer when the standard of care fails.
Phase 3 EMBARK trial results show promising survival benefits of combination therapy in patients with nmHSPC.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.